MADRIGAL PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 26, 2025

MDGL$432.60-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Preferred stock · Common stock · Additional paid-in Capital · Accumulated other comprehensive income (loss) · Accumulated deficit · Total stockholders’ equity
Shares · Amount · Shares · Amount
Balance at December 31, 2021	1,969,797	$—			17,103,395		$2			$863,495			$(80)			$(667,310)		$196,107
Issuance of common and preferred shares in equity offering, excluding to related parties, net of transaction costs	400,000	—			783,344		—			255,382			—			—		255,382
Sale of common shares to related parties and exercise of common stock options, net of transaction costs	—	—			215,784		—			8,955			—			—		8,955
Stock-based compensation expense related to equity-classified awards	—	—			—		—			31,625			—			—		31,625
Unrealized gain on marketable securities	—	—			—		—			—			48			—		48
Hercules warrant	—	—		—		—		622			—		—		622
Net loss	—	—			—		—			—			—			(295,350)		(295,350)
Balance at December 31, 2022	2,369,797	$—			18,102,523		$2			$1,160,079			$(32)			$(962,660)		$197,389
Issuance of common shares in equity offerings, excluding to related parties, net of transaction costs	—	—			1,346,199		—			260,187			—			—		260,187
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs	—	—			426,705		—			270,292			—			—		270,292
Stock-based compensation expense related to equity-classified awards	—	—			—		—			49,735			—			—		49,735
Unrealized gain on marketable securities	—	—			—		—			—			500			—		500
Hercules warrant	—	—			—		—			860			—			—		860
Net loss	—	—			—		—			—			—			(373,630)		(373,630)
Balance at December 31, 2023	2,369,797	$—			19,875,427		$2			$1,741,153			$468			$(1,336,290)		$405,333
Issuance of common shares in equity offerings, excluding to related parties, net of transaction costs	—	—		1,096,153		—		397,487		—		—		397,487
Sale of warrants and common shares to related parties and exercise of common stock options, net of transaction costs	—	—		1,033,099		—		337,575		—		—		337,575
Stock-based compensation expense related to equity-classified awards	—	—		—		—		79,880		—		—		79,880
Net loss	—	—		—		—		—		—		(465,892)			(465,892)
Balance at December 31, 2024	2,369,797		$—			22,004,679			$2			$2,556,095			$468		$(1,802,182)		$754,383

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.